A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice

  • Autoimmune Disorder
  • Rheumatoid Arthritis
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:

Completed

This trial runs in
Cities
  • Aalst
  • Amel
  • Bonheiden
  • Brugge
  • Bruxelles
  • Charleroi
  • Damme
  • Edegem
  • Genk
  • Gent
  • Lier
  • luik
  • Malle
  • Mechelen
  • Oostende
  • Turnhout
Trial Identifier:

NCT03291457 ML39114

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This prospective, multicenter, observational study will evaluate the use of concomitant glucocorticoid therapy in adults with rheumatoid arthritis (RA) being treated with tocilizumab in daily clinical practice. Participants will be observed for up to 52 weeks after starting treatment with tocilizumab. All visits and assessments will be performed as per routine clinical practice, with no study-specific visits or interventions.

      Hoffmann-La Roche Sponsor
      NCT03291457,ML39114 Trial Identifier
      Tocilizumab, Glucocorticoid Agent Treatments
      Rheumatoid Arthritis Condition
      Official Title

      A Prospective Non-Interventional Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Diagnosis of moderate to severe RA, defined as DAS28 greater than or equal to 3.7
      • Naive to tocilizumab, or received tocilizumab within 8 weeks prior to enrollment
      • Physician has made decision to commence IV or SC tocilizumab in accordance with label and reimbursement criteria
      • Treated with glucocorticoids for RA when starting tocilizumab treatment
      Exclusion Criteria
      • Treatment with any investigational agent within 4 weeks or 5 half-lives before tocilizumab
      • Continuous or regular treatment with oral corticosteroids for any indication other than RA

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Trials

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Rheumatoid Arthritis

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now